Method
Level · gp.fundamentals.capex_revenue_ratio
Raw value 0.01% · OPTIONAL
· Biological Products, (No Diagnostic Substances)
RESEARCH SNAPSHOTVir Biotechnology, Inc.'s latest supported as-filed period reports revenue of $238.9M, 19582.5% above the comparable as-filed period. Every value below links to its SEC accession and metric lineage.
No material rule-based research observation currently meets GrossPattern's Insight value threshold. Current state, direction, and filing evidence remain available below.
A multidimensional view of the latest comparable filing—not a composite score or recommendation.
Level · gp.fundamentals.capex_revenue_ratio
Raw value 0.01% · OPTIONAL
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value 51.61% · OPTIONAL
Yoy · gp.fundamentals.revenue
Raw value 19582.54% · CORE
Level · gp.fundamentals.gross_margin
Raw value 100.00% · CORE
Level · gp.fundamentals.operating_margin
Raw value 30.75% · CORE
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
Raw value 56.62% · OPTIONAL
Business direction, financial quality, capital allocation, and governance evidence remain separate—never collapsed into a recommendation score.
Interpretation boundary Direction describes measurable company fundamentals. Governance reports observable evidence only; it does not grade management character or predict stock returns.
Latest available comparable states within 180 days, normalized with robust median/MAD statistics.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Cash & equivalents changed +32.0% from the comparable as-filed period.
Net income changed +172.2% from the comparable as-filed period.
Operating income changed +162.0% from the comparable as-filed period.
Operating margin changed +978503 basis points from the comparable as-filed period.
Each point keeps the date investors could first observe it and its accession.
VIR · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001628280-26-056108SEC ↗10-QAug 5, 2026Period Jun 30, 20260001628280-26-053549SEC ↗8-KAug 5, 2026Period Aug 5, 20260001628280-26-053351SEC ↗8-KJul 24, 2026Period Jul 20, 20260001628280-26-049499SEC ↗4Jun 10, 2026Period Jun 9, 20260001628280-26-042326SEC ↗8-KJun 10, 2026Period Jun 9, 20260001628280-26-042237SEC ↗4Jun 2, 2026Period Jun 1, 20260001628280-26-039943SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Level · gp.fundamentals.sbc_revenue_ratio
Raw value 5.19% · OPTIONAL
Research & development changed +38.7% from the comparable as-filed period.
Revenue changed +19582.5% from the comparable as-filed period.
Selling, general & administrative changed +35.5% from the comparable as-filed period.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001628280-26-039938